MBX Biosciences is advancing a unique prodrug pipeline with key GLP-1 assets and a pivotal Phase 2 readout in ...

Many folks in NC can’t access Ozempic due to limited insurance coverage. But policy changes and falling prices may expand ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Biopharma Industry Landscape Report—uncover key trends in obesity, oncology, immunology, and AI, plus top stock picks and ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Blue Cross plans are retreating from GLP-1 weight-loss drug coverage after spending hundreds of millions of dollars on the ...

According to the company, eligible customers are now able to access six months of "prescription-only" Wegovy at a new and affordable price for $549 per month.

Plans to lift limits on child benefit payments and calls to restore the winter fuel allowance lead the papers.

Rosie O'Donnell revealed her weight loss journey after using Mounjaro and moving to Ireland with her child Clay in January ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.